{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T23:00:19Z","timestamp":1648681219252},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.cpet.2017.11.008","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T22:36:05Z","timestamp":1519425365000},"page":"239-248","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non\u2013 18 F-2-Fluoro-2-Deoxy- d -Glucose PET\/Computed Tomography in Gynecologic Oncology"],"prefix":"10.1016","volume":"13","author":[{"given":"Ashwini","family":"Kalshetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2017.11.008_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1102\/1470-7330.2012.0007","article-title":"The role of FDG-PET\/CT in gynaecological cancers","volume":"12","author":"Rockall","year":"2012","journal-title":"Canc Imag"},{"key":"10.1016\/j.cpet.2017.11.008_bib2","unstructured":"Key statistics about ovarian cancer. Available at: https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html\/lovarian. Accessed October 13, 2017."},{"issue":"3","key":"10.1016\/j.cpet.2017.11.008_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2013.01.017","article-title":"The value of 18F-FDG PET\/CT in recurrent gynecologic malignancies prior to pelvic exenteration","volume":"129","author":"Burger","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2017.11.008_bib4","first-page":"2196","article-title":"Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study","volume":"36","author":"Lapela","year":"1995","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2017.11.008_bib5","first-page":"1051","article-title":"Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET","volume":"44","author":"Torizuka","year":"2003","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2017.11.008_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2016.00153","article-title":"Choline metabolism alteration: a focus on ovarian cancer","volume":"6","author":"Bagnoli","year":"2016","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2017.11.008_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1095-0397(00)00097-2","article-title":"31. Clinical application of [C-11]acetate in oncology","volume":"3","author":"Liu","year":"2000","journal-title":"Clin Positron Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2017.11.008_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2017.11.008_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2013.07.099","article-title":"Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer","volume":"131","author":"Argenta","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cpet.2017.11.008_bib10","unstructured":"What Are the Key Statistics About Ovarian Cancer? Available at: https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html\/lovarian. Accessed October 13, 2017."},{"issue":"7","key":"10.1016\/j.cpet.2017.11.008_bib11","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.cpet.2017.11.008_bib12","first-page":"386","article-title":"A\u00a0pilot study of a novel poly (ADP-ribose) polymerase-1 (PARP) PET tracer ([18F]FluorThanatrace) in patients with ovarian carcinoma","volume":"58","author":"Pantel","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2017.11.008_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11307-012-0554-2","article-title":"Evaluation of 2-deoxy-2-18F-fluoro-D-glucose- and 3'-deoxy-3'-18F-fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer","volume":"14","author":"Perumal","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.cpet.2017.11.008_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12967-015-0511-3","article-title":"Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer","volume":"13","author":"Bauerschlag","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"2","key":"10.1016\/j.cpet.2017.11.008_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1021\/mp500628g","article-title":"Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model","volume":"12","author":"Ocak","year":"2015","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.cpet.2017.11.008_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2967\/jnumed.115.167072","article-title":"Preclinical 89Zr Immuno-PET of high-grade serous ovarian cancer and lymph node metastasis","volume":"57","author":"Sharma","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2017.11.008_bib17","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s00259-009-1158-1","article-title":"Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab","volume":"36","author":"Niu","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.cpet.2017.11.008_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2967\/jnumed.107.041301","article-title":"In\u00a0vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft","volume":"48","author":"Nagengast","year":"2007","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2017.11.008_bib19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00259-007-0427-0","article-title":"18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression","volume":"34","author":"Wu","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 7","key":"10.1016\/j.cpet.2017.11.008_bib20","doi-asserted-by":"crossref","first-page":"vii27","DOI":"10.1093\/annonc\/mds268","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Colombo","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2017.11.008_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12149-009-0230-z","article-title":"Role of carbon-11 choline PET\/CT in the management of uterine carcinoma: initial experience","volume":"23","author":"Sofue","year":"2009","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2017.11.008_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MNM.0000000000000641","article-title":"Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET\/CT of cervical primary squamous cell carcinoma","volume":"38","author":"Xu","year":"2017","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1016\/j.cpet.2017.11.008_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/IGC.0000000000000097","article-title":"Comparison of tumor volume between PET and MRI in cervical cancer with hybrid PET\/MR","volume":"24","author":"Zhang","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2017.11.008_bib24","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.ijrobp.2011.06.1411","article-title":"F-18 fluorothymidine (FLT) PET imaging for weekly evaluation of tumor response to chemoradiation therapy in patients with cervical cancer","volume":"81","author":"McGuire","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.cpet.2017.11.008_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/RLU.0b013e3182638e7e","article-title":"Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET\/CT","volume":"37","author":"Vercellino","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2017.11.008_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.107.048520","article-title":"Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone)","volume":"49","author":"Dehdashti","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2017.11.008_bib27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/0284186X.2010.510145","article-title":"Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer","volume":"49","author":"Schuetz","year":"2010","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2017.11.008_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11307-007-0095-2","article-title":"Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix","volume":"9","author":"Grigsby","year":"2007","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"10.1016\/j.cpet.2017.11.008_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2967\/jnumed.113.126615","article-title":"A\u00a0comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers","volume":"55","author":"Carlin","year":"2014","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2017.11.008_bib30","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2967\/jnumed.108.052316","article-title":"Correlating EGFR expression with receptor-binding properties and Internalization of 64Cu-DOTA-Cetuximab in 5 cervical cancer cell lines","volume":"49","author":"Eiblmaier","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2017.11.008_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2015.01.348","article-title":"Comparison of FLT- and FDG-PET in gynecological cancers","volume":"137","author":"Cho","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2017.11.008_bib32","first-page":"1618","article-title":"Imaging of uterine carcinoma by carbon-11-methionine and PET","volume":"35","author":"Lapela","year":"1994","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2017.11.008_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1148\/radiol.2482071379","article-title":"Uterine tumors: pathophysiologic imaging with 16alpha-18Ffluoro-17beta-estradiol and 18F fluorodeoxyglucose PET\u2013initial experience","volume":"248","author":"Tsujikawa","year":"2008","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.cpet.2017.11.008_bib34","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.108.060145","article-title":"Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET","volume":"50","author":"Tsujikawa","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2017.11.008_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00259-010-1589-8","article-title":"Functional oestrogen receptor \u03b1 imaging in endometrial carcinoma using 16\u03b1-18Ffluoro-17\u03b2-oestradiol PET","volume":"38","author":"Tsujikawa","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2017.11.008_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2967\/jnumed.112.113472","article-title":"18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis","volume":"54","author":"Zhao","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2017.11.008_bib37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-011-1851-8","article-title":"Additional value of 16\u03b1-18Ffluoro-17\u03b2-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on 18Ffluorodeoxyglucose PET","volume":"38","author":"Yoshida","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.cpet.2017.11.008_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12149-012-0597-0","article-title":"18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma","volume":"26","author":"Yamane","year":"2012","journal-title":"Ann Nucl Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859817301347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859817301347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T17:08:33Z","timestamp":1603904913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859817301347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1556859817301347"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2017.11.008","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non\u201318F-2-Fluoro-2-Deoxy-d-Glucose PET\/Computed Tomography in Gynecologic Oncology","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}